450 related articles for article (PubMed ID: 31400383)
41. Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies.
Xie B; Wan J; Chen X; Han W; Wang H
Mol Cancer Ther; 2020 Mar; 19(3):822-834. PubMed ID: 31848296
[TBL] [Abstract][Full Text] [Related]
42. Balancing the stability and drug activation in adaptive nanoparticles potentiates chemotherapy in multidrug-resistant cancer.
Wan J; Huang L; Cheng J; Qi H; Jin J; Wang H
Theranostics; 2021; 11(9):4137-4154. PubMed ID: 33754053
[No Abstract] [Full Text] [Related]
43. Carbonic anhydrase IX-directed immunoliposomes for targeted drug delivery to human lung cancer cells in vitro.
Wong BC; Zhang H; Qin L; Chen H; Fang C; Lu A; Yang Z
Drug Des Devel Ther; 2014; 8():993-1001. PubMed ID: 25092965
[TBL] [Abstract][Full Text] [Related]
44. PEGylated Liposomes of Meloxicam: Optimization by Quality by Design, in vitro Characterization and Cytotoxicity Evaluation.
Shaji J; Menon I
Pharm Nanotechnol; 2017; 5(2):119-137. PubMed ID: 28462699
[TBL] [Abstract][Full Text] [Related]
45. Stable and efficient delivery of docetaxel by micelle-encapsulation using a tripodal cyclotriphosphazene amphiphile.
Jun YJ; Jadhav VB; Min JH; Cui JX; Chae SW; Choi JM; Kim IS; Choi SJ; Lee HJ; Sohn YS
Int J Pharm; 2012 Jan; 422(1-2):374-80. PubMed ID: 22079718
[TBL] [Abstract][Full Text] [Related]
46. Targeted Delivery of Combination Therapeutics Using Monoclonal Antibody 2C5-Modified Immunoliposomes for Cancer Therapy.
Narayanaswamy R; Torchilin VP
Pharm Res; 2021 Mar; 38(3):429-450. PubMed ID: 33655395
[TBL] [Abstract][Full Text] [Related]
47. Liposomes assembled from dimeric retinoic acid phospholipid with improved pharmacokinetic properties.
Lu L; Du Y; Ismail M; Ling L; Yao C; Fu Z; Li X
Eur J Pharm Sci; 2018 Jan; 112():186-194. PubMed ID: 29162478
[TBL] [Abstract][Full Text] [Related]
48. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
[TBL] [Abstract][Full Text] [Related]
49. Characterization of pegylated and non-pegylated liposomal formulation for the delivery of hypoxia activated vinblastine-N-oxide for the treatment of solid tumors.
Shah VM; Nguyen DX; Alfatease A; Bracha S; Alani AW
J Control Release; 2017 May; 253():37-45. PubMed ID: 28302582
[TBL] [Abstract][Full Text] [Related]
50. Process optimization and in vivo performance of docetaxel loaded PHBV-TPGS therapeutic vesicles: A synergistic approach.
Vardhan H; Mittal P; Adena SKR; Upadhyay M; Yadav SK; Mishra B
Int J Biol Macromol; 2018 Mar; 108():729-743. PubMed ID: 29111267
[TBL] [Abstract][Full Text] [Related]
51. A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug.
Stevens PJ; Sekido M; Lee RJ
Pharm Res; 2004 Dec; 21(12):2153-7. PubMed ID: 15648245
[TBL] [Abstract][Full Text] [Related]
52. Bisphosphonate-functionalized coordination polymer nanoparticles for the treatment of bone metastatic breast cancer.
He Y; Huang Y; Huang Z; Jiang Y; Sun X; Shen Y; Chu W; Zhao C
J Control Release; 2017 Oct; 264():76-88. PubMed ID: 28842315
[TBL] [Abstract][Full Text] [Related]
53. Preparation and characterization of polymeric pH-sensitive STEALTH® nanoparticles for tumor delivery of a lipophilic prodrug of paclitaxel.
Lundberg BB
Int J Pharm; 2011 Apr; 408(1-2):208-12. PubMed ID: 21296135
[TBL] [Abstract][Full Text] [Related]
54. Liposomal formulation of hypoxia activated prodrug for the treatment of ovarian cancer.
Shah VM; Nguyen DX; Al Fatease A; Patel P; Cote B; Woo Y; Gheewala R; Pham Y; Huynh MG; Gannett C; Rao DA; Alani AWG
J Control Release; 2018 Dec; 291():169-183. PubMed ID: 30339904
[TBL] [Abstract][Full Text] [Related]
55. Characterization of organ-specific immunoliposomes for delivery of 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung-metastasis model.
Mori A; Kennel SJ; van Borssum Waalkes M; Scherphof GL; Huang L
Cancer Chemother Pharmacol; 1995; 35(6):447-56. PubMed ID: 7882453
[TBL] [Abstract][Full Text] [Related]
56. Prodrugs in combination with nanocarriers as a strategy for promoting antitumoral efficiency.
Lin MH; Hung CF; Hsu CY; Lin ZC; Fang JY
Future Med Chem; 2019 Aug; 11(16):2131-2150. PubMed ID: 31538520
[TBL] [Abstract][Full Text] [Related]
57. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells.
Luo Y; Ling Y; Guo W; Pang J; Liu W; Fang Y; Wen X; Wei K; Gao X
J Control Release; 2010 Oct; 147(2):278-88. PubMed ID: 20655966
[TBL] [Abstract][Full Text] [Related]
58. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
59. NGR-modified pH-sensitive liposomes for controlled release and tumor target delivery of docetaxel.
Gu Z; Chang M; Fan Y; Shi Y; Lin G
Colloids Surf B Biointerfaces; 2017 Dec; 160():395-405. PubMed ID: 28965079
[TBL] [Abstract][Full Text] [Related]
60. Folate-targeted docetaxel-lipid-based-nanosuspensions for active-targeted cancer therapy.
Wang L; Li M; Zhang N
Int J Nanomedicine; 2012; 7():3281-94. PubMed ID: 22802688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
